This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: A, B, R.sup.1, R.sup.2 and R.sup.3 are each as described herein, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by CB2 receptor binding activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, gastroesophageal reflux disease (GERD), constipation, diarrhea, functional gastrointestinal disorder, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, chronic obstructive pulmonary disease (COPD), cryptogenic fibrosing alveolitis or bronchitis. ##STR00001##

Pfizer Inc.

Benzimidazolone derivatives as CB2 receptor ligands

This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein A, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, m and n are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment of a condition mediated by CB2 receptor activity such as, but not limited to, inflammatory pain, nociceptive pain, neuropathic pain, fibromyalgia, chronic low back pain, visceral pain, acute cerebral ischemia, pain, chronic pain, acute pain, post herpetic neuralgia, neuropathies, neuralgia, diabetic neuropathy, HIV-related neuropathy, nerve injury, rheumatoid arthritic pain, osteoarthritic pain, back pain, cancer pain, dental pain, fibromyalgia, neuritis, sciatica, inflammation, neurodegenerative disease, cough, broncho constriction, irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), colitis, cerebrovascular ischemia, emesis such as cancer chemotherapy-induced emesis, rheumatoid arthritis, asthma, Crohn's disease, ulcerative colitis, asthma, dermatitis, seasonal allergic rhinitis, GERD, constipation, diarrhea, functional gastrointestinal disorders, irritable bowel syndrome, cutaneous T cell lymphoma, multiple sclerosis, osteoarthritis, psoriasis, systemic lupus erythematosus, diabetes, glaucoma, osteoporosis, glomerulonephritis, renal ischemia, nephritis, hepatitis, cerebral stroke, vasculitis, myocardial infarction, cerebral ischemia, reversible airway obstruction, adult respiratory disease syndrome, COPD, cryptogenic fibrosing alveolitis and bronchitis. ##STR00001##

Pfizer Inc

Sulfonyl benzimidazole derivatives

An acid-modified arabinogalactan protein composition, having an arabinose-galactaose ratio of less than 3.5:1, comprising 5 10% Rha, 20 35% Gal, and less than 5% Glc, prepared from Astragalus membranaceus, is useful for treating a number of conditions. For example, an acid-modified arabinogalactan protein composition having features of the invention is useful for stimulating hematopolesis, inducing the proliferation of megakaryocytes, inducing the maturation of megakaryocytes, and stimulating the production of IL-1.beta., IL-6, TNF-.alpha., IFN-.gamma., GM-CSF, G-CSF, and neutrophils, and stimulating the action of neutrophils; stimulating the immune and/or hematopoietic system of a mammal suffering from neutropenia, anemia, thrombocytopenia, exposure to cytotoxic agents, exposure to radiation, cachexia, emesis, and drug withdrawal symptoms; and is effective to restore the immune response to infection, in immunosuppressive conditions, and to protect hepatic cells in hepatitis B.

Pharmagenesis, Inc.

Acid-modified arabinogalactan protein composition

A compound having the following structure: ##STR00001## or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, Parkinson's disease, levodopa-induced dyskinesia, Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, Alzheimer's disease, epilepsy, schizophrenia, anxiety, depression, insomnia, nausea, emesis, alcohol disorders, drug addictions such as opiates, nicotine, cocaine, alcohol and psychostimulants, hypertension, circulatory shock, myocardial reperfusion injury, atherosclerosis, asthma, glaucoma, retinopathy, cancer, inflammatory bowel disease, acute and chronic liver disease such as hepatitis and liver cirrhosis, arthritis and osteoporosis.

hepatitis/opkast

Benzimidazolone derivatives as CB2 receptor ligands

Sulfonyl benzimidazole derivatives

Acid-modified arabinogalactan protein composition

Urea compounds and their use as enzyme inhibitors

Urea compounds and their use as enzyme inhibitors

Den mest komplette database med medicinske urter understøttet af videnskab